Search

Your search keyword '"Agaram, Narasimhan"' showing total 497 results
Start Over Author "Agaram, Narasimhan"
497 results on '"Agaram, Narasimhan"'

2. Deep Learning-Based Objective and Reproducible Osteosarcoma Chemotherapy Response Assessment and Outcome Prediction

Author

Ho, David Joon, Agaram, Narasimhan P., Jean, Marc-Henri, Suser, Stephanie D., Chu, Cynthia, Vanderbilt, Chad M., Meyers, Paul A., Wexler, Leonard H., Healey, John H., Fuchs, Thomas J., and Hameed, Meera R.

Subjects
Computer Science - Computer Vision and Pattern Recognition
Abstract

Osteosarcoma is the most common primary bone cancer whose standard treatment includes pre-operative chemotherapy followed by resection. Chemotherapy response is used for predicting prognosis and further management of patients. Necrosis is routinely assessed post-chemotherapy from histology slides on resection specimens where necrosis ratio is defined as the ratio of necrotic tumor to overall tumor. Patients with necrosis ratio >=90% are known to have better outcome. Manual microscopic review of necrosis ratio from multiple glass slides is semi-quantitative and can have intra- and inter-observer variability. We propose an objective and reproducible deep learning-based approach to estimate necrosis ratio with outcome prediction from scanned hematoxylin and eosin whole slide images. We collected 103 osteosarcoma cases with 3134 WSIs to train our deep learning model, to validate necrosis ratio assessment, and to evaluate outcome prediction. We trained Deep Multi-Magnification Network to segment multiple tissue subtypes including viable tumor and necrotic tumor in pixel-level and to calculate case-level necrosis ratio from multiple WSIs. We showed necrosis ratio estimated by our segmentation model highly correlates with necrosis ratio from pathology reports manually assessed by experts where mean absolute differences for Grades IV (100%), III (>=90%), and II (>=50% and <90%) necrosis response are 4.4%, 4.5%, and 17.8%, respectively. We successfully stratified patients to predict overall survival with p=10^-6 and progression-free survival with p=0.012. Our reproducible approach without variability enabled us to tune cutoff thresholds, specifically for our model and our data set, to 80% for OS and 60% for PFS. Our study indicates deep learning can support pathologists as an objective tool to analyze osteosarcoma from histology for assessing treatment response and predicting patient outcome.

Published
2022

6. Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma

Author

Gounder, Mrinal M, Agaram, Narasimhan P, Trabucco, Sally E, Robinson, Victoria, Ferraro, Richard A, Millis, Sherri Z, Krishnan, Anita, Lee, Jessica, Attia, Steven, Abida, Wassim, Drilon, Alexander, Chi, Ping, Angelo, Sandra P D’, Dickson, Mark A, Keohan, Mary Lou, Kelly, Ciara M, Agulnik, Mark, Chawla, Sant P, Choy, Edwin, Chugh, Rashmi, Meyer, Christian F, Myer, Parvathi A, Moore, Jessica L, Okimoto, Ross A, Pollock, Raphael E, Ravi, Vinod, Singh, Arun S, Somaiah, Neeta, Wagner, Andrew J, Healey, John H, Frampton, Garrett M, Venstrom, Jeffrey M, Ross, Jeffrey S, Ladanyi, Marc, Singer, Samuel, Brennan, Murray F, Schwartz, Gary K, Lazar, Alexander J, Thomas, David M, Maki, Robert G, Tap, William D, Ali, Siraj M, and Jin, Dexter X

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Genetics, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Biotechnology, Clinical Research, Human Genome, Genetic Testing, Aetiology, 2.1 Biological and endogenous factors, Good Health and Well Being, Biomarkers, Tumor, Bone Neoplasms, Genomics, Humans, Mutation, Osteosarcoma, Prospective Studies, Sarcoma
Abstract

There are more than 70 distinct sarcomas, and this diversity complicates the development of precision-based therapeutics for these cancers. Prospective comprehensive genomic profiling could overcome this challenge by providing insight into sarcomas' molecular drivers. Through targeted panel sequencing of 7494 sarcomas representing 44 histologies, we identify highly recurrent and type-specific alterations that aid in diagnosis and treatment decisions. Sequencing could lead to refinement or reassignment of 10.5% of diagnoses. Nearly one-third of patients (31.7%) harbor potentially actionable alterations, including a significant proportion (2.6%) with kinase gene rearrangements; 3.9% have a tumor mutational burden ≥10 mut/Mb. We describe low frequencies of microsatellite instability (

Published
2022

8. Deep Interactive Learning: An Efficient Labeling Approach for Deep Learning-Based Osteosarcoma Treatment Response Assessment

Author

Ho, David Joon, Agaram, Narasimhan P., Schueffler, Peter J., Vanderbilt, Chad M., Jean, Marc-Henri, Hameed, Meera R., and Fuchs, Thomas J.

Subjects
Electrical Engineering and Systems Science - Image and Video Processing, Computer Science - Computer Vision and Pattern Recognition, Quantitative Biology - Quantitative Methods
Abstract

Osteosarcoma is the most common malignant primary bone tumor. Standard treatment includes pre-operative chemotherapy followed by surgical resection. The response to treatment as measured by ratio of necrotic tumor area to overall tumor area is a known prognostic factor for overall survival. This assessment is currently done manually by pathologists by looking at glass slides under the microscope which may not be reproducible due to its subjective nature. Convolutional neural networks (CNNs) can be used for automated segmentation of viable and necrotic tumor on osteosarcoma whole slide images. One bottleneck for supervised learning is that large amounts of accurate annotations are required for training which is a time-consuming and expensive process. In this paper, we describe Deep Interactive Learning (DIaL) as an efficient labeling approach for training CNNs. After an initial labeling step is done, annotators only need to correct mislabeled regions from previous segmentation predictions to improve the CNN model until the satisfactory predictions are achieved. Our experiments show that our CNN model trained by only 7 hours of annotation using DIaL can successfully estimate ratios of necrosis within expected inter-observer variation rate for non-standardized manual surgical pathology task., Comment: Accepted at MICCAI 2020

Published
2020
Full Text
View/download PDF

11. Detection of GRM1 gene rearrangements in chondromyxoid fibroma: a comparison of fluorescence in‐situ hybridisation, RNA sequencing and immunohistochemical analysis.

Author

Torrence, Dianne, Dermawan, Josephine K, Zhang, Yanming, Vanderbilt, Chad, Hwang, Sinchun, Mullaney, Kerry, Jungbluth, Achim, Rao, Mamta, Gao, Kate, Sukhadia, Purvil, Linos, Konstantinos, Agaram, Narasimhan, and Hameed, Meera

Subjects
GENE rearrangement, RNA sequencing, GENE expression, PROTEIN overexpression, GENE fusion, ANAPLASTIC lymphoma kinase
Abstract

Aims: Chondromyxoid fibroma (CMF) is a rare, benign bone tumour which arises primarily in young adults and is occasionally diagnostically challenging. Glutamate metabotropic receptor 1 (GRM1) gene encodes a metabotropic glutamate receptor and was recently shown to be up‐regulated in chondromyxoid fibroma through gene fusion and promoter swapping. The aim of this study was to interrogate cases of CMF for the presence of GRM1 gene rearrangements, gene fusions and GRM1 protein overexpression. Methods and results: Selected cases were subjected to testing by fluorescent in‐situ hybridisation (FISH) with a GRM1 break‐apart probe, a targeted RNA sequencing method and immunohistochemical study with an antibody to GRM1 protein. Two cases were subjected to whole transcriptomic sequencing. In 13 of 13 cases, GRM1 protein overexpression was detected by immunohistochemistry using the GRM1 antibody. Of the 12 cases successfully tested by FISH, nine of 12 showed GRM1 rearrangements by break‐apart probe assay. Targeted RNA sequencing analysis did not detect gene fusions in any of the eight cases tested, but there was an increase in GRM1 mRNA expression in all eight cases. Two cases subjected to whole transcriptomic sequencing (WTS) showed elevated GRM1 expression and no gene fusions. Conclusion: GRM1 gene rearrangements can be detected using FISH break‐apart probes in approximately 75% of cases, and immunohistochemical detection of GRM1 protein over‐expression is a sensitive diagnostic method. The gene fusion was not detected by targeted RNA sequencing, due most probably to the complexity of fusion mechanism, and is not yet a reliable method for confirming a diagnosis of CMF in the clinical setting. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets

Author

Nacev, Benjamin A., Sanchez-Vega, Francisco, Smith, Shaleigh A., Antonescu, Cristina R., Rosenbaum, Evan, Shi, Hongyu, Tang, Cerise, Socci, Nicholas D., Rana, Satshil, Gularte-Mérida, Rodrigo, Zehir, Ahmet, Gounder, Mrinal M., Bowler, Timothy G., Luthra, Anisha, Jadeja, Bhumika, Okada, Azusa, Strong, Jonathan A., Stoller, Jake, Chan, Jason E., Chi, Ping, D’Angelo, Sandra P., Dickson, Mark A., Kelly, Ciara M., Keohan, Mary Louise, Movva, Sujana, Thornton, Katherine, Meyers, Paul A., Wexler, Leonard H., Slotkin, Emily K., Glade Bender, Julia L., Shukla, Neerav N., Hensley, Martee L., Healey, John H., La Quaglia, Michael P., Alektiar, Kaled M., Crago, Aimee M., Yoon, Sam S., Untch, Brian R., Chiang, Sarah, Agaram, Narasimhan P., Hameed, Meera R., Berger, Michael F., Solit, David B., Schultz, Nikolaus, Ladanyi, Marc, Singer, Samuel, and Tap, William D.

Published
2022
Full Text
View/download PDF

13. Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma

Author

D’Angelo, Sandra P., Richards, Allison L., Conley, Anthony P., Woo, Hyung Jun, Dickson, Mark A., Gounder, Mrinal, Kelly, Ciara, Keohan, Mary Louise, Movva, Sujana, Thornton, Katherine, Rosenbaum, Evan, Chi, Ping, Nacev, Benjamin, Chan, Jason E., Slotkin, Emily K., Kiesler, Hannah, Adamson, Travis, Ling, Lilan, Rao, Pavitra, Patel, Shreyaskumar, Livingston, Jonathan A., Singer, Samuel, Agaram, Narasimhan P., Antonescu, Cristina R., Koff, Andrew, Erinjeri, Joseph P., Hwang, Sinchun, Qin, Li-Xuan, Donoghue, Mark T. A., and Tap, William D.

Published
2022
Full Text
View/download PDF

16. Validation of a digital pathology system including remote review during the COVID-19 pandemic

Author

Hanna, Matthew G., Reuter, Victor E., Ardon, Orly, Kim, David, Sirintrapun, Sahussapont Joseph, Schüffler, Peter J., Busam, Klaus J., Sauter, Jennifer L., Brogi, Edi, Tan, Lee K., Xu, Bin, Bale, Tejus, Agaram, Narasimhan P., Tang, Laura H., Ellenson, Lora H., Philip, John, Corsale, Lorraine, Stamelos, Evangelos, Friedlander, Maria A., Ntiamoah, Peter, Labasin, Marc, England, Christine, Klimstra, David S., and Hameed, Meera

Published
2020
Full Text
View/download PDF

19. Supplementary Table S3 from PDGFRβ Signaling Cooperates with β-Catenin to Modulate c-Abl and Biologic Behavior of Desmoid-Type Fibromatosis

Author

Hu, Jia, primary, Hameed, Meera R., primary, Agaram, Narasimhan P., primary, Whiting, Karissa A., primary, Qin, Li-Xuan, primary, Villano, Anthony M., primary, O'Connor, Rachael B., primary, Rozenberg, Julian M., primary, Cohen, Sonia, primary, Prendergast, Katherine, primary, Kryeziu, Sara, primary, White, Richard L., primary, Posner, Mitchell C., primary, Socci, Nicholas D., primary, Gounder, Mrinal M., primary, Singer, Samuel, primary, and Crago, Aimee M., primary

Published
2024
Full Text
View/download PDF

20. Data from PDGFRβ Signaling Cooperates with β-Catenin to Modulate c-Abl and Biologic Behavior of Desmoid-Type Fibromatosis

Author

Hu, Jia, primary, Hameed, Meera R., primary, Agaram, Narasimhan P., primary, Whiting, Karissa A., primary, Qin, Li-Xuan, primary, Villano, Anthony M., primary, O'Connor, Rachael B., primary, Rozenberg, Julian M., primary, Cohen, Sonia, primary, Prendergast, Katherine, primary, Kryeziu, Sara, primary, White, Richard L., primary, Posner, Mitchell C., primary, Socci, Nicholas D., primary, Gounder, Mrinal M., primary, Singer, Samuel, primary, and Crago, Aimee M., primary

Published
2024
Full Text
View/download PDF

21. Supplementary Data 1 from PDGFRβ Signaling Cooperates with β-Catenin to Modulate c-Abl and Biologic Behavior of Desmoid-Type Fibromatosis

Author

Hu, Jia, primary, Hameed, Meera R., primary, Agaram, Narasimhan P., primary, Whiting, Karissa A., primary, Qin, Li-Xuan, primary, Villano, Anthony M., primary, O'Connor, Rachael B., primary, Rozenberg, Julian M., primary, Cohen, Sonia, primary, Prendergast, Katherine, primary, Kryeziu, Sara, primary, White, Richard L., primary, Posner, Mitchell C., primary, Socci, Nicholas D., primary, Gounder, Mrinal M., primary, Singer, Samuel, primary, and Crago, Aimee M., primary

Published
2024
Full Text
View/download PDF

26. PDGFRβ signaling cooperates with β-catenin to modulate c-Abl and biologic behavior of desmoid-type fibromatosis

Author

Hu, Jia, primary, Hameed, Meera R., additional, Agaram, Narasimhan P., additional, Whiting, Karissa A., additional, Qin, Li-Xuan, additional, Villano, Anthony M., additional, O'Connor, Rachael B., additional, Rozenberg, Julian M., additional, Cohen, Sonia, additional, Prendergast, Katherine, additional, Kryeziu, Sara, additional, White, Richard L., additional, Posner, Mitchell C., additional, Socci, Nicholas D., additional, Gounder, Mrinal M., additional, Singer, Samuel, additional, and Crago, Aimee M., additional

Published
2023
Full Text
View/download PDF

31. Implementation of Digital Pathology Offers Clinical and Operational Increase in Efficiency and Cost Savings

Author

Hanna, Matthew G., Reuter, Victor E., Samboy, Jennifer, England, Christine, Corsale, Lorraine, Fine, Samson W., Agaram, Narasimhan P., Stamelos, Evangelos, Yagi, Yukako, Hameed, Meera, Klimstra, David S., and Sirintrapun, S. Joseph

Subjects
Workflow software -- Economic aspects, Return on investment -- Economic aspects, Surgical clinics -- Economic aspects, Surgery, Benchmarking, Workflow software, Return on investment, Health, Memorial Sloan-Kettering Cancer Center
Abstract

Context.--Digital pathology (DP) implementations vary in scale, based on aims of intended operation. Few laboratories have completed a full-scale DP implementation, which may be due to high overhead costs that disrupt the traditional pathology workflow. Neither standardized criteria nor benchmark data have yet been published showing practical return on investment after implementing a DP platform. Objective.--To provide benchmark data and practical metrics to support operational efficiency and cost savings in a large academic center. Design.--Metrics reviewed include archived pathology asset retrieval; ancillary test request for recurrent/meta-static disease; cost analysis and turnaround time (TAT); and DP experience survey. Results.--Glass slide requests from the department slide archive and an off-site surgery center showed a 93% and 97% decrease, respectively. Ancillary immunohistochemical orders, compared in 2014 (52%)--before whole slide images (WSIs) were available in the laboratory information system--and 2017 (21%) showed $114 000/y in anticipated savings. Comprehensive comparative cost analysis showed a 5-year $1.3 million savings. Surgical resection cases with prior WSIs showed a 1-day decrease in TAT. A DP experience survey showed 80% of respondents agreed WSIs improved their clinical sign-out experience. Conclusions.--Implementing a DP operation showed a noteworthy increase in efficiency and operational utility. Digital pathology deployments and operations may be gauged by the following metrics: number of glass slide requests as WSIs become available, decrease in confirmatory testing for patients with metastatic/recurrent disease, long-term decrease in off-site pathology asset costs, and faster TAT. Other departments may use our benchmark data and metrics to enhance patient care and demonstrate return on investment to justify adoption of DP. doi: 10.5858/arpa.2018-0514-OA, Applications for digital pathology (DP) have seen increased growth; however, few departments have successfully implemented a full-scale operation of a DP platform. Digital pathology has tremendous potential to disrupt the [...]

Published
2019
Full Text
View/download PDF

38. Supplementary Tables S1 - S7 from Integrin-α10 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma

Author

Okada, Tomoyo, primary, Lee, Ann Y., primary, Qin, Li-Xuan, primary, Agaram, Narasimhan, primary, Mimae, Takahiro, primary, Shen, Yawei, primary, O'Connor, Rachael, primary, López-Lago, Miguel A., primary, Craig, Amanda, primary, Miller, Martin L., primary, Agius, Phaedra, primary, Molinelli, Evan, primary, Socci, Nicholas D., primary, Crago, Aimee M., primary, Shima, Fumi, primary, Sander, Chris, primary, and Singer, Samuel, primary

Published
2023
Full Text
View/download PDF

39. Data from Integrin-α10 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma

Author

Okada, Tomoyo, primary, Lee, Ann Y., primary, Qin, Li-Xuan, primary, Agaram, Narasimhan, primary, Mimae, Takahiro, primary, Shen, Yawei, primary, O'Connor, Rachael, primary, López-Lago, Miguel A., primary, Craig, Amanda, primary, Miller, Martin L., primary, Agius, Phaedra, primary, Molinelli, Evan, primary, Socci, Nicholas D., primary, Crago, Aimee M., primary, Shima, Fumi, primary, Sander, Chris, primary, and Singer, Samuel, primary

Published
2023
Full Text
View/download PDF

40. Supplementary Figures S1 - S8 from Integrin-α10 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma

Author

Okada, Tomoyo, primary, Lee, Ann Y., primary, Qin, Li-Xuan, primary, Agaram, Narasimhan, primary, Mimae, Takahiro, primary, Shen, Yawei, primary, O'Connor, Rachael, primary, López-Lago, Miguel A., primary, Craig, Amanda, primary, Miller, Martin L., primary, Agius, Phaedra, primary, Molinelli, Evan, primary, Socci, Nicholas D., primary, Crago, Aimee M., primary, Shima, Fumi, primary, Sander, Chris, primary, and Singer, Samuel, primary

Published
2023
Full Text
View/download PDF

41. Supplementary Figure Legends from Integrin-α10 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma

Author

Okada, Tomoyo, primary, Lee, Ann Y., primary, Qin, Li-Xuan, primary, Agaram, Narasimhan, primary, Mimae, Takahiro, primary, Shen, Yawei, primary, O'Connor, Rachael, primary, López-Lago, Miguel A., primary, Craig, Amanda, primary, Miller, Martin L., primary, Agius, Phaedra, primary, Molinelli, Evan, primary, Socci, Nicholas D., primary, Crago, Aimee M., primary, Shima, Fumi, primary, Sander, Chris, primary, and Singer, Samuel, primary

Published
2023
Full Text
View/download PDF

43. Data from Rb and p53-Deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma Require Skp2 for Survival

Author

Li, George Z., primary, Okada, Tomoyo, primary, Kim, Young-Mi, primary, Agaram, Narasimhan P., primary, Sanchez-Vega, Francisco, primary, Shen, Yawei, primary, Tsubokawa, Norifumi, primary, Rios, Jordan, primary, Martin, Axel S., primary, Dickson, Mark A., primary, Qin, Li-Xuan, primary, Socci, Nicholas D., primary, and Singer, Samuel, primary

Published
2023
Full Text
View/download PDF

44. Supplementary Data #1 from Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma

Author

Zhu, Guo Gord, primary, Nafa, Khedoudja, primary, Agaram, Narasimhan, primary, Zehir, Ahmet, primary, Benayed, Ryma, primary, Sadowska, Justyna, primary, Borsu, Laetitia, primary, Kelly, Ciara, primary, Tap, William D., primary, Fabbri, Nicola, primary, Athanasian, Edward, primary, Boland, Patrick J., primary, Healey, John H., primary, Berger, Michael F., primary, Ladanyi, Marc, primary, and Hameed, Meera, primary

Published
2023
Full Text
View/download PDF

45. Supplementary Figure 2 from Rb and p53-Deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma Require Skp2 for Survival

Author

Li, George Z., primary, Okada, Tomoyo, primary, Kim, Young-Mi, primary, Agaram, Narasimhan P., primary, Sanchez-Vega, Francisco, primary, Shen, Yawei, primary, Tsubokawa, Norifumi, primary, Rios, Jordan, primary, Martin, Axel S., primary, Dickson, Mark A., primary, Qin, Li-Xuan, primary, Socci, Nicholas D., primary, and Singer, Samuel, primary

Published
2023
Full Text
View/download PDF

46. Supplementary Figure 6 from Rb and p53-Deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma Require Skp2 for Survival

Author

Li, George Z., primary, Okada, Tomoyo, primary, Kim, Young-Mi, primary, Agaram, Narasimhan P., primary, Sanchez-Vega, Francisco, primary, Shen, Yawei, primary, Tsubokawa, Norifumi, primary, Rios, Jordan, primary, Martin, Axel S., primary, Dickson, Mark A., primary, Qin, Li-Xuan, primary, Socci, Nicholas D., primary, and Singer, Samuel, primary

Published
2023
Full Text
View/download PDF

47. Supplementary Data from A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced Sarcoma

Author

Gounder, Mrinal M., primary, Rosenbaum, Evan, primary, Wu, Nian, primary, Dickson, Mark A., primary, Sheikh, Tahir N., primary, D'Angelo, Sandra P., primary, Chi, Ping, primary, Keohan, Mary Lou, primary, Erinjeri, Joseph P., primary, Antonescu, Cristina R., primary, Agaram, Narasimhan, primary, Hameed, Meera R., primary, Martindale, Moriah, primary, Lefkowitz, Robert A., primary, Crago, Aimee M., primary, Singer, Sam, primary, Tap, William D., primary, Takebe, Naoko, primary, Qin, Li-Xuan, primary, and Schwartz, Gary K., primary

Published
2023
Full Text
View/download PDF

48. Supplementary Data from Rb and p53-Deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma Require Skp2 for Survival

Author

Li, George Z., primary, Okada, Tomoyo, primary, Kim, Young-Mi, primary, Agaram, Narasimhan P., primary, Sanchez-Vega, Francisco, primary, Shen, Yawei, primary, Tsubokawa, Norifumi, primary, Rios, Jordan, primary, Martin, Axel S., primary, Dickson, Mark A., primary, Qin, Li-Xuan, primary, Socci, Nicholas D., primary, and Singer, Samuel, primary

Published
2023
Full Text
View/download PDF

49. Supplementary Data #3 from Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma

Author

Zhu, Guo Gord, primary, Nafa, Khedoudja, primary, Agaram, Narasimhan, primary, Zehir, Ahmet, primary, Benayed, Ryma, primary, Sadowska, Justyna, primary, Borsu, Laetitia, primary, Kelly, Ciara, primary, Tap, William D., primary, Fabbri, Nicola, primary, Athanasian, Edward, primary, Boland, Patrick J., primary, Healey, John H., primary, Berger, Michael F., primary, Ladanyi, Marc, primary, and Hameed, Meera, primary

Published
2023
Full Text
View/download PDF

50. Data from A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced Sarcoma

Author

Gounder, Mrinal M., primary, Rosenbaum, Evan, primary, Wu, Nian, primary, Dickson, Mark A., primary, Sheikh, Tahir N., primary, D'Angelo, Sandra P., primary, Chi, Ping, primary, Keohan, Mary Lou, primary, Erinjeri, Joseph P., primary, Antonescu, Cristina R., primary, Agaram, Narasimhan, primary, Hameed, Meera R., primary, Martindale, Moriah, primary, Lefkowitz, Robert A., primary, Crago, Aimee M., primary, Singer, Sam, primary, Tap, William D., primary, Takebe, Naoko, primary, Qin, Li-Xuan, primary, and Schwartz, Gary K., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results